Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Core Viewpoint - Intensity Therapeutics, Inc. reported its second quarter 2025 financial results and provided updates on its clinical studies, highlighting progress in cancer therapy development and capital raises to extend its operational runway [1][5][6]. Corporate Update - The INVINCIBLE-4 Study is a Phase 2 trial analyzing the efficacy of INT230-6 in combination with standard of care for early-stage triple-negative breast cancer, with the primary endpoint being the change in pathological complete response rate [2][3]. - The INVINCIBLE-3 Study is a Phase 3 trial testing INT230-6 as a monotherapy for specific soft tissue sarcoma subtypes, with overall survival as the primary endpoint; patient enrollment was paused due to funding issues, but treatment for enrolled patients continues [4][7]. - The company has raised a total of $11.3 million since the beginning of Q2 2025, extending its cash runway into the second half of 2026 [5][11]. Financial Results - Research and development expenses for Q2 2025 were $1.5 million, a decrease from $3.6 million in Q2 2024, primarily due to lower costs associated with the INVINCIBLE-3 Study [7]. - General and administrative expenses were $1.2 million for Q2 2025, down from $1.5 million in the same period in 2024, attributed to cost-saving measures [8]. - The net loss for Q2 2025 was $2.5 million, compared to a net loss of $5.0 million in Q2 2024, indicating improved financial performance [9][15]. Product Information - INT230-6 is the lead investigational product candidate designed for direct intratumoral injection, combining cisplatin and vinblastine sulfate with a penetration enhancer to improve drug dispersion within tumors [10][13]. - The drug has shown promising results in preclinical models, achieving a 100% complete response rate in malignant peripheral nerve sheath tumors [11].